扶正合剂联合化疗治疗老年晚期非小细胞肺癌疗效观察

[目的] 观察扶正合剂联合GP方案化疗治疗老年晚期非小细胞肺癌患者的临床疗效和毒副反应。[方法] 选择50例经明确诊断的老年晚期非小细胞肺癌患者,随机分为两组,A组给予吉西他滨加卡铂方案(GP方案)静脉化疗,B组加用扶正合剂口服,28 d为1个周期,连续观察2个化疗周期。[结果] 在缩小瘤体方面,B组临床受益率优于A组,差异有统计学意义(P<0.05);在降低血清肿瘤标志物方面,两组治疗前后癌胚抗原(CEA)水平变化差异有统计学意义(P<0.05),细胞角质素19片段(CYFRA-21)水平变化差异无统计学意义(P>0.05);两组患者在免疫功能、卡氏评分、临床症状改善方面,差异有统计性意义(P<0.05);在毒副反应方面,恶心呕吐、白细胞减少的B组发生率较A组低,两组差异均有统计学意义(P<0.05).[结论] 扶正合剂对老年晚期非小细胞肺癌化疗具有增效减毒的治疗作用。

Effect of Fuzheng mistura combined with chemotherapy on patients with non-small cell lung cancer in senile advanced stage

[Objective] To observe the effect and side reaction of Fuzheng mistura combined with GP scheme chemotherapy on patients with non-small cell lung cancer in senile advanced stage. [Methods] Fifty patients with confirmed diagnosis of advanced non-small cell lung cancer were enrolled. They were randomly divided into two groups. Group A was given with gemcitabine plus carboplatin solution chemotherapy intravenously, and group B with Fuzheng mistura orally. Twenty-eight days was a course and the treatment was continuously used for two chemotherapy courses. [Results] Fuzheng mistura in chemotherapy of older patients with advanced non small cell lung cancer had a therapeutic effect. In decreasing the cancer size the clinical benefit rate of group B was better than that of group A with significant difference (P<0.05). In reducing the serum tumor markers, the change of CEA level had significant difference (P<0.05) of both groups before and after treatment. There was no statistical difference in CYFRA-21 level (P>0.05). There was significant difference (P<0.05) between two groups of patients in the improvement of immune function, casparian score, clinical symptoms. A significant differences were also found in side reactions, nausea vomiting, decreasing of leucocyte count. Their incidence in group B was lower than that in group A. [Conclusion] Fuzheng mistura has effect-increasing and detoxification effect in chemotherapy in older patients with advanced non small cell lung cancer.